Genorare Secures Pre-Seed Funding to Revolutionize Rare Disease Diagnosis with AI
NLC Health Ventures is proud to announce the launch and initial funding of Genorare, a pioneering company set to dramatically shorten the diagnostic journey for individuals with rare diseases. Backed by the Health Impact Fund, Genorare aims to find answers faster for rare disease patients by bridging critical gaps in diagnosis. The company is achieving this with an end-to-end, AI-powered platform that uses a suite of cutting-edge technologies, including: Large Language Models (LLMs), predictive analytics, and Fully Homomorphic Encryption (FHE). A key innovation is the use of FHE, a next-generation privacy technology that allows for advanced analysis while ensuring patient data remains completely secure, promising a new standard of care for the rare disease community.
Founded by NLC Health Ventures in collaboration with Dr. Quy Vo-Reinhard, a serial entrepreneur and digital health leader, Genorare is built to empower patients, clinicians, and researchers worldwide, without compromising data. Dr. Quy Vo-Reinhard, PhD (Computational Biomedicine, RWTH Aachen) and MBA (EBS), is a digital health entrepreneur with 20 years of experience in bioinformatics, AI, and data privacy. She co-founded multiple ventures across Europe and Asia, including the Web3-based dHealth. A lecturer at Swiss universities, she brings deep expertise and a global network to lead Genorare’s mission to transform rare disease diagnosis.
“Rare disease patients often endure a diagnostic odyssey lasting 5–8 years. Genorare is here to change that with secure, real-time, AI-driven insights that help identify rare conditions earlier, while protecting their privacy”, said Dr. Vo-Reinhard, CEO of Genorare B.V.
About Genorare
Rare diseases pose a significant challenge, often leading to years of diagnostic odyssey and immense patient suffering due to the complexity and scarcity of information. Genorare directly addresses this critical need by providing a secure and efficient platform that integrates LLMs, FHE, and real-time Electronic Health Record (EHR) analysis. This innovative approach significantly reduces diagnostic timelines, ensuring patients receive the right care sooner.
Genorare’s proprietary technology is built on a robust, privacy-first framework. It collects patients' genomic data, EHR, and lab data, encrypting it at the source without any data leaving a secure environment. This encrypted data is then processed using homomorphic encryption, enabling complex computations and pattern detection — including analysis via the Human Phenotype Ontology (HPO) database and advanced Natural Language Processing (NLP) models — without ever decrypting sensitive patient information. This ensures unparalleled data privacy and security, guaranteeing full GDPR and HIPAA compliance.
The platform's secure and compliant nature facilitates seamless adoption across hospitals, research institutions, and pharmaceutical companies, enabling collaborative advancements in rare disease research and treatment development. By providing personalized insights and decryption only at the point of care by authorized personnel, Genorare empowers clinicians with actionable intelligence while meticulously protecting patient confidentiality.
"Genorare is not just a scientific breakthrough, it’s a compelling business case,” said Dr. Kathrin Ballesteros Katemann, Venture Partner at NLC Health Ventures.
“With an enormous unmet need in rare disease diagnosis and a highly scalable privacy-first platform, Genorare is uniquely positioned to lead this new frontier in precision health.”
Next Steps
The company has already received a pre-seed investment from NLC’s captive fund, the Health Impact Fund, to launch the MVP, which is targeted for Q3 2025. Genorare is engaging with hospitals, research centers, and pharmaceutical partners in Europe and Asia for early pilots. The platform will support both SaaS diagnostics for clinicians and clinical trial matching services for pharma, enabling earlier detection, patient stratification, and precision enrollment in rare disease studies.
About NLC Health Ventures
NLC Health Ventures, based in Amsterdam, is the most active health technology investor in Europe and the world’s largest healthtech venture builder. NLC finds, builds, and scales transformative health innovations with the goal of providing more patients with quality care. NLC is a so-called ‘BCorp,’ its funds comply with SFDR9 guidelines, and they contribute to ESG 3, 9, and 17. With more than 100 start-ups, 4 funds, and activity in 16 countries, they bring impactful innovations to patients on a large scale. The NLC Health Impact Fund is NLC’s newest and largest fund to date, investing in NLC’s start-ups. The fund deploys capital for ventures at various stages, providing both initial and follow-up funding.
For more information:
Quy Vo-Reinhard, Ph.D
CEO, Genorare B.V.
📧 quy.voreinhard@genorare.com
🌐 www.genorare.com
https://www.linkedin.com/company/genorare-b-v/
%2520980x600.jpeg)
.webp)
